Disclosure statement
MH has received speaking fees from Asahi Kasei Pharma Corporation and Ono Pharmaceutical Co., Ltd. MM has received speaking fees from Mitsubishi-Tanabe Pharma Corporation and Janssen Pharmaceutical KK, and manuscript fees from Sanofi KK. MK has received speaking fees from Eisai Co. Ltd, Chugai Pharma Co. Ltd, Mitsubishi-Tanabe Pharma, Bristol-Myers Squibb, Janssen Pharma KK, Astellas Pharma Inc, Takeda Pharma Co., Nippon Kayaku Co. Ltd, Daiichi-Sankyo Co. Ltd, Asahi Kasei Pharma Co., and AbbVie Japan. SK and YS have no conflicts of interest. YM has received grants from Asahi Kasei Pharmaceutical Co. Ltd, Chugai Pharmaceutical Co. Ltd, Ono Pharmaceutical Co. Ltd, Daiichi-Sankyo Co. Ltd, Teijin Pharma Ltd, Eisai Co. Ltd, Nippon Kayaku Co. Ltd, and Mitsubishi-Tanabe Pharma Corporation, instructor fees from Asahi Kasei Pharmaceutical Co. Ltd, Kissei Pharmaceutical Co. Ltd, and Janssen Pharmaceutical KK Eisai Co. Ltd, and speaking fees from Ono Pharmaceutical Co. Ltd, Mitsubishi-Tanabe Pharma Corporation, Astellas Pharma Inc, UCB Japan Co. Ltd, Chugai Pharmaceutical Co. Ltd, AbbVie Japan, Daiichi-Sankyo Co. Ltd, AYUMI Pharmaceutical Corporation, Janssen Pharmaceutical KK, Takeda Pharmaceutical Co. Ltd, Sanofi KK, Teijin Pharma Ltd, Eli Lilly Japan KK, and Eisai Co. Ltd.